Live Cell Imaging Market

The global live cell imaging market in terms of revenue was estimated to be worth $2.7 billion in 2023 and is poised to reach $4.3 billion by 2028, growing at a CAGR of 10.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and growing availability of funds for research. On the other hand, the high cost of high-content screening systems is restraining the growth of this market.

Live Cell Imaging Market - Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Live Cell Imaging Market

Live Cell Imaging Market Dynamics

Driver: Growing availability of funds for research

The growing availability of funds for research will drive R&D in the pharmaceutical and biotechnology industries. The governments and various treatment centers of several countries are also promoting and supporting cell-based research. A large portion of government funding is provided to academic research societies (such as Maryland Stem Cell Research Commission, International Human Frontier Science Program Organization (HFSPO), National Institutes of Health (NIH), etc.) to promote cell-based research to advance the diagnostic and therapeutic applications of various types of cells in managing chronic and infectious diseases. Moreover, the growing government funding in regenerative medicine research is expected to drive the demand for advanced live cell imaging technologies, including high-resolution microscopy, image analysis software, and data management tools.

Restraint: High cost of high-content screening systems

The high cost of high-content screening (HCS) systems is one of the major factors restraining the growth of the market. HCS systems are specialized instruments that are designed to automate the process of acquiring and analyzing large amounts of data from live cells. These systems are typically expensive, and the cost can vary depending on the complexity and capabilities of the system.

The high cost of HCS systems can be a barrier for smaller research labs and institutions that may not have the budget to invest in these systems. Additionally, the cost of maintenance, consumables, and software can also add up over time, making it challenging for researchers to sustain the use of HCS systems in their research.

Opportunity: Increasing adoption of live cell imaging technologies in emerging markets

Emerging markets like China, India, and Brazil have experienced rapid expansion in the life science and biotechnology sectors in recent years. Live cell imaging can be used in a variety of fields, including cancer, regenerative medicine, and drug development. These regions have a significant pool of talented researchers, physicians, and scientists who are actively pursuing research in these fields. Such developments in the pharmaceutical and biotechnology industries in these emerging countries are expected to create significant growth opportunities for players operating in the market.

Challenge: Image analysis and data management

Live cell imaging generates large volumes of data over time, presenting challenges in data storage, management, and analysis. Efficient data handling and storage solutions are required to manage the data generated from multiple imaging sessions. Additionally, advanced image analysis algorithms and software are necessary to extract meaningful information from acquired images and enable quantitative analysis of cellular processes. Live cell imaging often involves using multiple software tools and platforms for image acquisition, analysis, and data management. Integrating these tools into a cohesive workflow can be challenging due to compatibility issues, data transfer, and standardization of file formats. Researchers need to ensure seamless data flow between different software packages, facilitate interoperability, and establish standardized protocols to streamline the analysis process.

The instruments segment dominated live cell imaging market by product & service:

The instruments segment held the largest share of the global market in 2022. Live cell imaging instruments provide critical insights into the fundamental nature of cellular and tissue function. Several end users opt for automated instruments over manually operated instruments as they are more efficient and provide accurate results. The instruments used in live cell imaging are significantly more expensive than the consumables and software used in these procedures. Additional factors such as the launch of new and advanced instruments, the increasing incidence of diseases, and rising government initiatives and awareness programs to promote cell-based research are the other major factors driving the demand for live cell imaging instruments. The increasing demand for live cells for analysis in the biotech and biopharmaceutical industries is another major factor supporting the adoption of these instruments.

To know about the assumptions considered for the study, download the pdf brochure

Asia Pacific is estimated to register the highest CAGR in the global live cell imaging market, during the forecast period.

The market in the Asia Pacific region has experienced significant growth over the past few years. This growth can be attributed to several factors such as increasing investment in healthcare infrastructure and research & development (R&D) activities. Governments and private entities are allocating substantial funds and launching various research programs to enhance healthcare facilities and promote scientific advancements, including live cell imaging technologies. These investments are driving the adoption of live cell imaging techniques across various applications and research fields. Furthermore, in countries such as China and Japan, factors such as rising prominence of regenerative medicine research, low manufacturing costs and the huge demand for medicines is expected to drive market growth, thereby increasing the demand for live cell imaging technologies for studying the cellular dynamics in details.

Key players in the live cell imaging market include Danaher (US), ZEISS Group (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer Inc. (US), Sartorius AG (Germany), Agilent Technologies, Inc. (US), Thermo Fisher Scientific, Inc. (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), NanoEnTek Inc. (South Korea), GE Healthcare (US), Bruker Corporation (US), Becton, Dickinson and Company (BD) (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Blue-Ray Biotech Corp. (Taiwan), CYTENA GmbH (Germany), Nanolive SA (Switzerland), Abberior (Germany), Phase Holographic Imaging (PHI) AB (Sweden), Cytoskeleton, Inc. (US), Corning Incorporated (US), KEYENCE Corporation (Japan), and Aligned Genetics, Inc. (South Korea).

Live Cell Imaging Market Report Scope

This report categorizes the live cell imaging market to forecast revenue and analyze trends in each of the following submarkets:

By Product &Service

• Instruments
  • Microscopes
  • Standalone Systems
  • Cell Analysers
  • Accessories
• Consumables
  • Reagents
  • Assay Kits
  • Media
  • Other Consumables
• Software
• Services 

By Application

• Cell Biology
• Stem Cells
• Developmental Biology
• Drug Discovery

By Technology

• Time-Lapse Microscopy
• Fluorescence Resonance Energy Transfer (FRET)
• Fluorescence Recovery After Photobleaching (FRAP)
• High Content Screening (HCS)
• Other Technologies

By End User

• Pharmaceutical & Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organisations

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
  • Brazil
  • RoLATAM
• Middle East and Africa (MEA)

Recent Developments

• In February 2023, Nikon Corporation launched the Nikon Spatial Array Confocal (NSPARC) detector for AX systems. This detector enables high-resolution imaging of live tissue with minimal phototoxicity.
• In January 2022, CytoSMART Technologies launched Omni Pro 12, adding to the Omni live cell imaging product portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst